ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain

• Published in: Orphanet journal of rare diseases Vol. 18; no. 1; pp. 4 - 11
• Main Authors: Poveda, José Luis, Gómez, Claudia, Gil, Alicia, Badia, Xavier
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.01.2023; BioMed Central; BMC
• Subjects: Drug Approval; Europe; Humans; Licensing, certification and accreditation; Management; Marketing; Orphan Drug Production; Orphan drugs; Prescription pricing; Prices and rates; Pricing; Regulatory Variables; Reimbursement; Spain; Europe; Spain; Orphan drugs; Reimbursement; Regulatory Variables; Pricing; Spain
• ISSN: 1750-1172; 1750-1172
• DOI: 10.1186/s13023-022-02610-4

The present study aims to assess clinical and regulatory variables that would influence pricing and reimbursement (P&R) decisions for Orphan Drugs (ODs) in Spain. ODs approved by the European Commission (EC) between 2006 and 2021 were classified according to their P&R status in Spain: approved, undergoing decision and rejected. A statistical analysis was carried out to assess the potential association between clinical and regulatory variables and P&R decision of ODs in Spain: therapeutic area, rarity of disease, existence of alternative therapies, availability of survival-related outcomes, safety profile, type of population, conditional approval status granted by the European Medicines Agency (EMA) and a positive Therapeutic Positioning Report (TPR) opinion. 111 ODs have been approved by the EC and have obtained marketing authorisation in Spain between 2006 and 2021. Out of the 111 ODs, 57 (51.4%) were reimbursed, 24 (21.6%) were undergoing decision and 30 (27%) were rejected. According to the statistical analysis, ODs with a positive TPR conclusion (p-value < 0.01), not subject to a conditional approval by the EMA (p-value < 0.05) and approved without the obligation to conduct a post-authorisation safety study (PASS) (p-value < 0.05), were statistically significant, and therefore, would be more likely to obtain P&R approval in Spain. This study shows that the TPR plays a key role in the P&R process in Spain and highlights that traditional evaluation tools, such us safety and efficacy, were the main drivers of P&R decisions for ODs. A positive conclusion of the TPR, non-conditional approval by the EMA and no obligation for a PASS seems to favourably affect P&R decisions in Spain.